Everything below concerns AOD-9604. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-11-24. Where a claim depends on a specific study, the study is described rather than over-claimed.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from a fragment of human growth hormone |
| Sequence basis | hGH residues 176-191 | Commonly described as a 16-amino-acid fragment |
| Appearance | White to off-white powder | Typical for lyophilized research peptides |
| Solubility | Soluble in water or aqueous buffer | Exact solubility depends on pH and purity |
| Common synonyms | AOD9604; hGH 176-191 | Spelling and punctuation vary across sources |
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
EC 1.1.99.9: pyridoxine 5-dehydrogenase EC 1.1.99.10: Now EC 1.1.5.9, glucose 1-dehydrogenase (FAD, quinone) EC 1.1.99.11: Now classified as EC 1.1.5.14, fructose 5-dehydrogenase EC 1.1.99.12: sorbose dehydrogenase EC 1.1.99.13: glucoside 3-dehydrogenase EC 1.1.99.14: glycolate dehydrogenase EC 1.1.99.15: Now EC 1.5.1.20, methylenetetrahydrofolate reductase [NAD(P)H] EC 1.1.99.16: Now EC EC 1.1.5.4, malate dehydrogenase (quinone) EC 1.1.99.17: Now EC 1.1.5.2, quinoprotein glucose dehydrogenase EC 1.1.99.18: cellobiose dehydrogenase (acceptor) EC 1.1.99.19: Now EC 1.17.99.4, uracil/thymine dehydrogenase EC 1.1.99.20: alkan-1-ol dehydrogenase (acceptor) EC 1.1.99.21: D-sorbitol dehydrogenase (acceptor) EC 1.1.99.22: glycerol dehydrogenase (acceptor) EC 1.1.99.23: Now EC 1.1.2.6, polyvinyl alcohol dehydrogenase (cytochrome) EC 1.1.99.24: hydroxyacid-oxoacid transhydrogenase EC 1.1.99.25: Now EC 1.1.5.8, quinate dehydrogenase (quinone), EC 1.1.99.26: 3-hydroxycyclohexanone dehydrogenase EC 1.1.99.27: (R)-pantolactone dehydrogenase (flavin) EC 1.1.99.28: glucose-fructose oxidoreductase EC 1.1.99.29: pyranose dehydrogenase (acceptor) EC 1.1.99.30: 2-oxoacid reductase EC 1.1.99.31: (S)-mandelate dehydrogenase EC 1.1.99.32: L-sorbose 1-dehydrogenase EC 1.1.99.33: Now EC 1.17.99.7, formate dehydrogenase (acceptor) EC 1.1.99.34: now EC 1.1.98.2, glucose-6-phosphate dehydrogenase (coenzyme-F420) EC 1.1.99.35: soluble quinoprotein glucose dehydrogenase EC 1.1.99.36: alcohol dehydrogenase (nicotinoprotein) EC 1.1.99.37: methanol dehydrogenase (nicotinoprotein) EC 1.1.99.38: 2-deoxy-scyllo-inosamine dehydrogenase (AdoMet-dependent) EC 1.1.99.39: D-2-hydroxyglutarate dehydrogenase EC 1.1.99.40: (R)-2-hydroxyglutarate—pyruvate transhydrogenase EC 1.1.99.41: 3-hydroxy-1,2-didehydro-2,3-dihydrotabersonine reductase EC 1.1.99.42: 4-pyridoxic acid dehydrogenase
Other reagents present in amounts greater than required to react with all the limiting reagent present are considered excess. As a result, the yield should not be automatically taken as a measure for reaction efficiency. In their 1992 publication General Chemistry, Whitten, Gailey, and Davis described the theoretical yield as the amount predicted by a stoichiometric calculation based on the number of moles of all reactants present. This calculation assumes that only one reaction occurs and that the limiting reactant reacts completely. According to Whitten, the actual yield is always smaller (the percent yield is less than 100%), often very much so, for several reasons. As a result, many reactions are incomplete and the reactants are not completely converted to products. If a reverse reaction occurs, the final state contains both reactants and products in a state of chemical equilibrium. Two or more reactions may occur simultaneously, so that some reactant is converted to undesired side products. Losses occur in the separation and purification of the desired product from the reaction mixture. Impurities are present in the starting material which do not react to give desired product.
== Mechanism of action == Bradykinin is a peptide-based hormone that is formed locally in tissues, very often in response to a trauma. It increases vessel permeability, dilates blood vessels and causes endotelial cells to contract. Bradykinin plays an important role as the mediator of pain. Surplus bradykinin is responsible for the typical symptoms of inflammation, such as swelling, redness, overheating and pain. These symptoms are mediated by activation of bradykinin B2 receptors. Icatibant acts as a bradykinin inhibitor by blocking the binding of native bradykinin to the bradykinin B2 receptor. Little is known about the effects of icatibant on the bradykinin B1 receptor.
Sources: en.wikipedia.org
==== Cyprus ==== The New York Times published an exposé revealing an extensive three-year phishing campaign aimed against diplomats based in Cyprus. After accessing the state system the hackers had access to the European Union's entire exchange database. By login into Coreu, hackers accessed communications linking all EU states, on both sensitive and not so sensitive matters. The event exposed poor protection of routine exchanges among European Union officials and a coordinated effort from a foreign entity to spy on another country. "After over a decade of experience countering Chinese cyberoperations and extensive technical analysis, there is no doubt this campaign is connected to the Chinese government", said Blake Darche, one of the Area 1 Security experts – the company revealing the stolen documents. The Chinese Embassy in the US did not return calls for comment. In 2019, another coordinated effort took place that allowed hackers to gain access to government (gov.cy) emails. Cisco's Talos Security Department revealed that "Sea Turtle" hackers carried out a broad piracy campaign in the DNS countries, hitting 40 different organizations, including Cyprus.
== History == The first standardized vector, pBR220, was designed in 1977 by researchers in Herbert Boyer's lab. The plasmid contains various restriction enzyme sites and a stable antibiotic-resistance gene free from transposon activities. In 1982, Jeffrey Vieira and Joachim Messing described the development of M13mp7-derived pUC vectors that consist of a multiple cloning site and allow for more efficient sequencing and cloning using a set of universal M13 primers. Three years later, the currently popular pUC19 plasmid was engineered by the same scientists.
== Non-insulin dependent (type 2) diabetes mellitus == The current releases of the downloadable AIDA software, and AIDA on-line, do not incorporate functions to model endogenous insulin secretion — which takes place in people with non-insulin dependent diabetes mellitus type 2, and healthy subjects without diabetes. Nevertheless, a wide number of people with insulin-treated type 2 diabetes mellitus have reported finding the AIDA diabetes simulator of use for learning about balancing insulin and diet in diabetes. This is because many of the principles of insulin dosage adjustment are remarkably similar in both type 1 and type 2 diabetes mellitus, and even without an endogenous insulin secretion model function, AIDA still can offer realistic simulations (from an educational perspective) for people with non-insulin dependent (type 2) diabetes mellitus. The AIDA developers have published a research paper in 2011 which includes reference to the incorporation of a dedicated function for pancreatic insulin secretion — to be added to a future release of the simulator.
==== Cell-based scheme of coagulation ==== A newer model of coagulation mechanism explains the intricate combination of cellular and biochemical events that occur during the coagulation process in vivo. Along with the procoagulant and anticoagulant plasma proteins, normal physiologic coagulation requires the presence of two cell types for formation of coagulation complexes: cells that express tissue factor (usually extravascular) and platelets. The coagulation process occurs in two phases. First is the initiation phase, which occurs in tissue-factor-expressing cells. This is followed by the propagation phase, which occurs on activated platelets. The initiation phase, mediated by the tissue factor exposure, proceeds via the classic extrinsic pathway and contributes to about 5% of thrombin production. The amplified production of thrombin occurs via the classic intrinsic pathway in the propagation phase; about 95% of thrombin generated will be during this second phase.
Sources: en.wikipedia.org
Rood." Chevreul stressed the importance of accurate portrayal of lighting in promoting realism, but added, "It is almost always so that accurate, yet exaggerated coloring is found more pleasing than absolute fidelity to the scene." Vincent van Gogh took the advice to heart, making lavish use of complementaries to intensify one another. Van Gogh wrote, "this reciprocal heightening is what's called the law of simultaneous contrast…If the complementary colors are taken at equal value, that is to say, at the same degree of brightness and light, their juxtaposition will raise both the one and the other to an intensity so violent that human eyes will scarcely be able to bear to look at it." Chevreul was also influential in twentieth-century painting, especially that of Robert Delaunay, who was introduced to Chevreul's theories by his friend Jean Metzinger. Delaunay's style of mixing relatively large blocks of near-complementaries is today usually known as Orphism. Delaunay himself, however, preferred the name "Simultanism," a clear nod to Chevreul. Chevreul is also linked to what is sometimes called Chevreul's illusion, the bright edges that seem to exist between adjacent strips of identical colors having different intensities. See Chevreul's The Laws of Contrast of Colour for more information.
13,802, 27 June 2008 - The SENSEX dropped by 600 points, to fall below the 14,000 mark, closing at 13,802. 12,962, 1 July 2008 - The SENSEX falls below the 13,000 mark, closing at 12,962. 11,802, 6 October 2008 - The SENSEX dropped by 724.62 points amid fears of the US recession and attempts by governments across the world to save their failing banks, to fall below the 12,000 mark, closing at 11,802. 10,527, 10 October 2008 - The SENSEX dropped by 800.51 points amid weak industrial production data and concerns over impact of global economic crisis on IT and banking firms in India, to fall below the 11,000 mark, closing at 10,527. 9,975, 17 October 2008 – The SENSEX crashes below the psychological 5-figure mark of 10,000 points, closing at 9,975.35, following extremely negative global financial indications in US and other countries. Just ten months earlier, in December 2007, SENSEX had closed above the 20,000 mark for the first time. 8,701.07, 24 October 2008 - The SENSEX lost 10.96% of its value (1070.63 points) on the intra-day trade, closing at 8,701.07, for its first close below the 9,000 mark since 14 June 2006, after RBI lowered its GDP growth forecasts on global economic concerns. The loss was the 2nd highest in terms of total points, and the 3rd highest percentage-wise, for a one-day period in the index's history. 8,509.56, 27 October 2008 - The SENSEX hit an intra-day low of 7,697.39, before closing at 8,509.56, for its lowest close since 14 November 2005.
Tyrosine is the non-essential amino acid precursor of melanin. Tyrosine is converted to dihydroxyphenylalanine (DOPA) via the enzyme tyrosinase. Then DOPA is polymerized into melanin. The copper-ion based enzyme-catalyzed oxidative transformation of catechol derivative dopa to light absorbing dopaquinone to indole-5,6-quinone is clearly seen following the polymerization to melanin, the color of the pigment ranges from red to dark brown.
Sources: en.wikipedia.org
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.
It is commonly described as a 16-amino-acid peptide based on residues 176-191 of human growth hormone. Some sources vary in notation, so checking the stated sequence is useful.
It is not typically described as a standalone natural hormone. The sequence is derived from the C-terminal region of human growth hormone, but the synthetic peptide is a laboratory-made construct.
Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.